Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081416 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16039763 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5233802 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5233794 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL792679 | 0.92 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30994163 | 0.92 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL2890236 | 0.92 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL5230913 | 0.85 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL21349755 | 0.83 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL7057207 | 0.82 | SLC6A3 (0.40) | CHRM2CHRM1CHRM3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825322-B1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| EP-3825322-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | Chengdu Sintanovo Biotechnology Co., Ltd (CN) | 2021-05-26 | — | — | EP | disclosed |
| US-20210139537-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| US-9526711-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139537-A1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | OPRL1, OPRK1, OPRM1 | CHRM2 603/4885CHRM1 607/4885CHRM3 196/4885 |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | OPRL1, OPRK1, OPRM1 | CHRM2 603/4885CHRM1 607/4885CHRM3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.